Results 131 to 140 of about 100,757 (302)

Insights from a 6‐year hair drug analysis compendium in drug‐facilitated sexual assault cases

Journal of Forensic Sciences, EarlyView.
Abstract Drug‐facilitated sexual assault (DFSA) may involve a diverse array of substances, including illicit drugs, prescription medications, and over‐the‐counter pharmaceuticals. Hair analysis has emerged as a valuable forensic tool, offering an extended window of detection spanning several months. However, interpreting drug concentrations in hair can
Amandine Fort, Coralie Boudin, Hélène Eysseric‐Guerin, Virginie Scolan, Jérémy Borges, François Chiron, Pierre Henry, Françoise Stanke‐Labesque, Théo Willeman   +8 more
wiley   +1 more source

Postpartum Depression: Overlap Between Symptom‐Based and Register‐Based Measures

Acta Psychiatrica Scandinavica, EarlyView.
ABSTRACT Introduction Postpartum depression (PPD) can be measured in various ways, including questionnaire‐based symptom scores or through administrative health databases. We examined the overlap between symptom‐based and register‐based PPD definitions and assessed the consistency in exposure‐outcome associations.
Sofie Egsgaard, Mette Bliddal, Mette‐Marie Zacher Kjeldsen, Xiaoqin Liu, Kathrine Bang Madsen, Merete Lund Mægbæk, Trine Munk‐Olsen   +6 more
wiley   +1 more source

Effectiveness of a Psychiatrist‐Led Clinic for Metabolic Health in Severe Mental Illness: A Retrospective Chart Review Study

Acta Psychiatrica Scandinavica, EarlyView.
ABSTRACT Background Psychotropic medications are associated with serious metabolic adverse effects, which contribute to an increased risk of cardiometabolic comorbidities in patients with severe mental illness (SMI). Several intervention strategies are available to mitigate these metabolic adverse effects; however, data on their utility in real‐world ...
Nicolette Stogios, Femin Prasad, Riddhita De, Kateryna Maksyutynska, Akash PrasannaKumar, Vittal Korann, Tariq Ahmed, Marcos Sanches, Leah Burton, Mohammed A. Alarabi, Tanner Isinger, Michelle Desanti, Rebecca Oliveira, Daphne J. Korczak, Ariel Graff‐Guerrero, Gary Remington, Margaret K. Hahn, Sri Mahavir Agarwal   +17 more
wiley   +1 more source

Parental attitudes toward the prescription of psychotropic medications for their children

Journal of Family and Community Medicine, 2008
Objective: To explore parental attitudes towards the prescription of psychotropic medication for their children. Method: A questionnaire built to collect socio-demographic data of parents and their attitudes was distributed among parents.
Fatima A Al-Haidar
doaj  

Psychedelic‐assisted treatment for substance use disorder: A narrative systematic review

Addiction, EarlyView.
Abstract Background and aims This is the first systematic review of the extant literature on all major psychedelic‐assisted treatment for alcohol use disorder (AUD), tobacco use disorder (TUD) and other substance use disorders (SUD). We aimed to summarise the evidence for efficacy of psychedelic‐assisted treatment for AUD, TUD, and SUD; to evaluate its
Theodore Piper, Francesca Small, Sam Brown, Michael Kelleher, Luke Mitcheson, James Rucker, Allan H. Young, John Marsden   +7 more
wiley   +1 more source

5‐Methoxy‐N,N‐dimethyltryptamine (5‐MeO‐DMT) for alcohol use disorder: An open‐label, phase 2, proof‐of‐concept, clinical trial

Addiction, EarlyView.
Abstract Background and Aims Psychedelic drugs may help treat alcohol use disorder (AUD). This study evaluated BPL‐003, a novel intranasal powder formulation of 5‐methoxy‐N,N‐dimethyltryptamine (5‐MeO‐DMT) benzoate salt, in people with moderate–severe AUD enrolled in a standard of care, 10‐week programme of relapse‐prevention oriented Cognitive ...
John Marsden, Michael Kelleher, Fiona Dunbar, Anna O. Ermakova, Luke Mitcheson, Claire Roberts, James J. Rucker, Gemma Scott, Ivan Saeger, Francesca Small, Mathieu Seynaeve   +10 more
wiley   +1 more source

Detecting cannabis use reduction through biochemical verification of urinary cannabinoids: An aggregated analysis of cannabis use disorder treatment trials examining average reductions and individual cut‐points

Addiction, EarlyView.
Abstract Background and aims Currently, there is no data‐driven cannabis reduction metric using biochemical verification, which represents a significant gap in cannabis harm reduction research, treatment and policy. Using aggregated data from 7 cannabis use disorder treatment trials, the aims of this analysis were to 1) determine if decreases in self ...
Erin A. McClure, Brian Neelon, Rachel L. Tomko, Ashley Dowd, Kevin M. Gray, Aimee L. McRae‐Clark, Nathaniel Baker   +6 more
wiley   +1 more source

Varenicline for cannabis use disorder: A randomized controlled trial

Addiction, EarlyView.
Abstract Background and aims Although cannabis use is widespread and prevalence of cannabis use disorder (CUD) is increasing, limited advancements have been made in CUD medication development. The objective of this study was to test the efficacy of varenicline with medical management for reducing cannabis use in treatment‐seeking individuals with CUD ...
Aimee L. McRae‐Clark, Kevin M. Gray, Nathaniel L. Baker, Brian J. Sherman, Bryan Tolliver, Jessica Burt, Alonzo Steplight, Elizabeth Chapman, Amanda Wagner   +8 more
wiley   +1 more source

Editorial for the Special Issue "The Identification of Narcotic and Psychotropic Drugs". [PDF]

Toxics
Basilicata P, Pieri M.
europepmc   +1 more source

Rare but relevant: Ibogaine and cardiovascular complications—prolonged QT interval and ventricular arrhythmias

Addiction, EarlyView.
Abstract Revived interest in psychedelic‐assisted therapies has also renewed focus on ibogaine, a psychoactive alkaloid, for its notable anti‐addictive potential. Evidence from observational, open‐label, and limited randomized placebo‐controlled trials indicates that ibogaine and its metabolite noribogaine reduce craving and withdrawal symptoms in ...
Tibor Markus Brunt
wiley   +1 more source